Kairos Pharma (KAPA) Price to Book (2024 - 2025)
Kairos Pharma's (KAPA) quarterly Price to Book came in at 0.15 in Q4 2025, down 95.91% on a YoY basis from 3.61 in Q4 2024, and down 92.96% quarter-over-quarter from 2.1 in Q2 2025.
Powered by 
Analysis
Kairos Pharma (KAPA) Price to Book (2024 - 2025) Analysis & Trends
Kairos Pharma (KAPA) has reported Price to Book for 2 consecutive years, with 0.15 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Price to Book fell 95.91% year-over-year to 0.15; the trailing twelve-month figure through Dec 2025 stood at 0.15 (down 95.91% YoY), and the FY2025 full-year result was 0.15, down 95.91% from the prior year.
- Price to Book slipped to 0.15 in Q4 2025 per KAPA's latest filing, from 2.1 in the prior quarter.
- Across five years, Price to Book topped out at 6.05 in Q3 2024 and bottomed at 0.15 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.58 Bn | 192.59 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.17 Bn | 176.99 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.59 Bn | 122.74 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.61 Bn | 73.61 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.24 Bn | 55.05 Bn | 1.37 Bn |
| 6 | Moderna | 54.29 Bn | 49.15 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 32.96 Bn | 29.65 Bn | 992.69 Mn |
| 8 | Biogen | 31.94 Bn | 30.66 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.38 Bn | 29.38 Bn | 1.16 Mn |
| 10 | Kairos Pharma | 30.41 Mn | 25.07 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 0.15 |
| Jun 30, 2025 | 2.10 |
| Mar 31, 2025 | 2.09 |
| Dec 31, 2024 | 3.61 |
| Sep 30, 2024 | 6.05 |